Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh

Heysell, Scott K; Ahmed, Shahriar; Rahman, Md. Toufiq; Akhanda, Md. Wahiduzzaman; Gleason, A. Tucker; Ebers, Andrew; Houpt, Eric R.

doi:10.1183/13993003.01778-2017

Cited by 19 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study published in JMA also showed severe ototoxicity by Kanamycin [16]. A prospective cohort study published in European Respiratory journal by Scott K. Heysell et al in 2017 showed more than 75% patients experienced hearing loss after Kanamycin treatment whereas in our study, only 20% of patients experienced mild to moderate hearing loss and only 2.5% showed severe sensorineural deafness [17]. In our study, only 20% of patients complained about auditory disturbances among which only 1 patients found to have severe sensorineural hearing loss confirmed by pure tone audiometry.…”

Section: Discussionsupporting

confidence: 55%

Clinical Profile of MDR-TB patients with special reference to kanamycin induced ototoxicity in a tertiary care hospital of eastern India

et al. 2019

View full text Add to dashboard Cite

Introduction: MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other anti-TB drugs. Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. Kanamycin, is an aminoglycoside antibiotic used to treat multi-drug resistant TB in the intensive phase. Objective: To analyze the patients of MDR-TB with respect to age, sex and presence of comorbidities like diabetes mellitus. Also to study the incidence of hearing impairments among patients of MDR-TB receiving injectable Kanamycin. Methods: 40 patients of MDR-TB diagnosed by sputum culture and drug susceptibility testing (DST) have been classified on the basis of age, sex and presence of diabetes mellitus. All have received injectable Kanamycin for 6months in their intensive phase (IP). Patients giving history of auditory impairments underwent pure tone audiometry (PTA) for detection of sensory neural hearing loss, if any. Result: Out of 40 patients of MDR-TB, 30 were males and the rest 10 were females. Age ranges from 12 to 70 years among which maximum patients fell in the age group of 21-30 years (12 patients). 16 patients were diabetic. After getting Kanamycin, 8 patients gave the history of auditory disturbances and only 1 patient found to have severe sensory neural hearing loss confirmed by pure tone audiometry.Conclusion: Prevalence of MDR-TB has been found more among males and in younger age group. Diabetes Mellitus play a major role here. Kanamycin induced hearing loss is not a very serious concern in our study.

show abstract

Section: Discussionsupporting

confidence: 55%

Clinical Profile of MDR-TB patients with special reference to kanamycin induced ototoxicity in a tertiary care hospital of eastern India

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition, there are several sequelae of MDR-TB treatment, which can be aggravated by multiple therapeutic cycles. Some studies indicate that 90% of the treated cases present some sequelae, the most common being pulmonary dysfunctions such as dyspnea and reduced vital capacity, hearing loss due to ototoxicity, loss of quality of life and social isolation 20 .…”

Section: Discussionmentioning

confidence: 99%

“…Além disso, há diversas sequelas do tratamento da TB-MDR, que podem ser agravadas pelos múltiplos ciclos terapêuticos. Alguns estudos apontam que 90% dos casos tratados apresentam alguma sequela, as mais comuns sendo disfunções pulmonares como dispneia e redução da capacidade vital, perdas auditivas devido à ototoxicidade, perda da qualidade de vida e isolamento social 20 .…”

Section: Discussionunclassified

Predictive model of unfavorable outcomes for multidrug-resistant tuberculosis

et al. 2019

View full text Add to dashboard Cite

OBJECTIVE: to analyze the temporal trend, identify the factors related and elaborate a predictive model for unfavorable treatment outcomes for multidrug-resistant tuberculosis (MDR-TB). METHODS: Retrospective cohort study with all cases diagnosed with MDR-TB between the years 2006 and 2015 in the state of São Paulo. The data were collected from the state system of TB cases notifications (TB-WEB). The temporal trend analyzes of treatment outcomes was performed through the Prais-Winsten analysis. In order to verify the factors related to the unfavorable outcomes, abandonment, death with basic cause TB and treatment failure, the binary logistic regression was used. Pictorial representations of the factors related to treatment outcome and their prognostic capacity through the nomogram were elaborated. RESULTS: Both abandonment and death have a constant temporal tendency, whereas the failure showed it as decreasing. Regarding the risk factors for such outcomes, using illicit drugs doubled the odds for abandonment and death. Besides that, being diagnosed in emergency units or during hospitalizations was a risk factor for death. On the contrary, having previous multidrug-resistant treatments reduced the odds for the analyzed outcomes by 33%. The nomogram presented a predictive model with 65% accuracy for dropouts, 70% for deaths and 80% for failure. CONCLUSIONS: The modification of the current model of care is an essential factor for the prevention of unfavorable outcomes. Through predictive models, as presented in this study, it is possible to develop patient-centered actions, considering their risk factors and increasing the chances for cure.

show abstract

“…Kanamisin dapat menimbulkan efek samping yang berat, yaitu ototoksik, gangguan elektrolit (hipokalemia, hipomagnesemia, hipokalsemia), dan gangguan fungsi ginjal (nefrotoksik). [1][2][3] Ototoksik oleh karena pemberian kanamisin dapat menimbulkan gangguan pendengaran (kokleotoksik) serta gangguan keseimbangan (vestibulotoksik). Kanamisin lebih dominan menyebabkan efek samping kokleotoksik berupa gangguan pendengaran dan atau tinnitus.…”

Section: Pendahuluanunclassified

“…Kepustakaan menyatakan bahwa diperlukan kewaspadaan khusus untuk para pasien yang sebelumnya pernah mendapatkan pengobatan streptomisin berkaitan dengan risiko efek samping pada pemberian kanamisin pengobatan TB RO. 3 Hasil penelitian sesuai dengan penelitian sebelumnya oleh Reviono dkk., 10,15 yaitu tidak terdapat hubungan antara riwayat pemberian streptomisin sebelumnya dengan timbulnya gangguan pendengaran.…”

Section: Pembahasanunclassified

Pengaruh Faktor Risiko terhadap Waktu Timbulnya Efek Samping Kanamisin pada Tuberkulosis Resistan Obat

Wati

Reviono

Putranto

et al. 2018

mkb

View full text Add to dashboard Cite

Kanamisin adalah obat untuk terapi tuberkulosis resistan obat (TB RO) yang menimbulkan efek samping gangguan pendengaran, gangguan fungsi ginjal, dan gangguan elektrolit terutama hipokalemia. Penelitian bertujuan menilai kesintasan waktu timbulnya efek samping dan pengaruh faktor risiko usia, riwayat terapi streptomisin serta berat badan terhadap efek samping akibat pemberian kanamisin pasien TB RO. Penelitian kohort retrospektif dari data rekam medis pasien TB RO dari Januari 2011 sampai April 2017 di RSUD Dr. Moewardi Surakarta. Analisis pengaruh faktor risiko terhadap efek samping menggunakan uji cox regression. Dari 238 pasien didapatkan gangguan pendengaran 143 pasien, gangguan fungsi ginjal 147 pasien, dan hipokalemia 169 pasien. Usia lebih dari 40 tahun hazard ratio (HR) 2,419

show abstract

Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh

Cited by 19 publications

References 13 publications

Clinical Profile of MDR-TB patients with special reference to kanamycin induced ototoxicity in a tertiary care hospital of eastern India

Clinical Profile of MDR-TB patients with special reference to kanamycin induced ototoxicity in a tertiary care hospital of eastern India

Predictive model of unfavorable outcomes for multidrug-resistant tuberculosis

Pengaruh Faktor Risiko terhadap Waktu Timbulnya Efek Samping Kanamisin pada Tuberkulosis Resistan Obat

Contact Info

Product

Resources

About